SFI
TRAW icon

Susquehanna Fundamental Investments’s Traws Pharma TRAW Stock Holding History

Susquehanna Fundamental Investments’s Portfolio TRAW Stock Details TRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,356
Closed -$30K – 1528
2022
Q3 		$30K Buy
+1,356
New +$41K ﹤0.01% 1387
2022
Q1 		$133K Hold
2,887
– – ﹤0.01% 1426
2021
Q4 		$184K Buy
2,887
+1,854
+179% +$149K ﹤0.01% 1268
2021
Q3 		$99K Buy
1,033
+36
+4% +$4.64K ﹤0.01% 1625
2021
Q2 		$173K Buy
+997
New +$226K ﹤0.01% 1513

Other funds holding TRAW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna Fundamental Investments's TRAW Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Traws Pharma (TRAW) in Q4 2022, closing a stake of 1,356 shares — an estimated $30K sold.

Susquehanna Fundamental Investments first reported a position in TRAW in Q2 2021 and held it in 5 quarters. The position peaked at $184K in Q4 2021. 28 funds tracked by Wall St. Rank hold TRAW as of Q4 2022.

  • Susquehanna Fundamental Investments reported no remaining Traws Pharma position as of Q4 2022 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 1,356 Traws Pharma shares in Q4 2022, an estimated $30K.
  • Susquehanna Fundamental Investments first reported a position in Traws Pharma in Q2 2021 and held it in 5 quarters.
  • Susquehanna Fundamental Investments's Traws Pharma position peaked at $184K in Q4 2021.
  • 28 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.